Moderna, Inc.

Moderna, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, founded in 2010. Its shares trade on Nasdaq under the ticker MRNA, and it is a member of the S&P 500 index. The company was built on the idea of using messenger RNA technology to develop medicines and vaccines.

In the messenger RNA approach, cells are given instructions to make a specific protein, which either triggers an immune response or has a therapeutic effect. Products the company has brought to market include the Spikevax vaccine against the coronavirus and the mRESVIA vaccine against respiratory syncytial virus. Its research pipeline includes vaccine candidates for influenza, cytomegalovirus and other infectious diseases, as well as personalized cancer treatments. Manufacturing is carried out at its own facilities and through partnerships.

When following Moderna stock, changes in vaccine policy, clinical trial results, seasonal vaccine demand and approval processes for new products are taken into account. On the MRNA page at Lzzo.com the price is shown in US dollars, and a price chart and technical indicators are available on the same page.